Veeva Systems’ (VEEV) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Veeva Systems (NYSE:VEEV) in a research note released on Monday, MarketBeat.com reports. Needham & Company LLC currently has a $270.00 price target on the technology company’s stock.

A number of other brokerages have also weighed in on VEEV. Oppenheimer raised their price objective on shares of Veeva Systems from $225.00 to $300.00 and gave the company an “outperform” rating in a report on Monday, August 17th. Wells Fargo & Company boosted their target price on shares of Veeva Systems from $317.00 to $320.00 and gave the stock an “overweight” rating in a research note on Thursday, June 4th. Mizuho dropped their target price on Veeva Systems from $295.00 to $270.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. Zacks Research cut Veeva Systems from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $225.00 price target on shares of Veeva Systems in a report on Thursday, June 4th. Nineteen investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $258.08.

Veeva Systems Stock Performance

Shares of Veeva Systems stock opened at $244.72 on Monday. Veeva Systems has a one year low of $148.05 and a one year high of $310.50. The company has a market cap of $39.75 billion, a PE ratio of 43.62, a P/E/G ratio of 1.06 and a beta of 0.92. The business has a 50-day simple moving average of $203.41 and a 200-day simple moving average of $183.04.

Veeva Systems (NYSE:VEEV) last issued its earnings results on Wednesday, August 26th. The technology company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.22 by $0.13. Veeva Systems had a net margin of 28.37% and a return on equity of 13.72%. The firm had revenue of $927.96 million for the quarter, compared to analysts’ expectations of $905.38 million. During the same quarter last year, the company earned $1.99 earnings per share. The firm’s revenue was up 17.6% compared to the same quarter last year. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. On average, sell-side analysts predict that Veeva Systems will post 6.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Veeva Systems

In other news, insider Thomas D. Schwenger sold 36,000 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $250.23, for a total value of $9,008,280.00. Following the completion of the transaction, the insider owned 19,449 shares in the company, valued at approximately $4,866,723.27. This represents a 64.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.60% of the company’s stock.

Institutional Investors Weigh In On Veeva Systems

Several hedge funds and other institutional investors have recently bought and sold shares of VEEV. SHP Wealth Management purchased a new position in shares of Veeva Systems during the fourth quarter worth about $26,000. Compass Financial Management LLC purchased a new stake in shares of Veeva Systems in the 2nd quarter valued at about $27,000. Activest Wealth Management lifted its holdings in shares of Veeva Systems by 3,175.0% in the 4th quarter. Activest Wealth Management now owns 131 shares of the technology company’s stock valued at $29,000 after purchasing an additional 127 shares during the last quarter. Arlington Trust Co LLC purchased a new stake in shares of Veeva Systems in the 2nd quarter valued at about $29,000. Finally, Field & Main Bank acquired a new stake in shares of Veeva Systems in the 2nd quarter valued at about $29,000. 88.20% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Veeva reported second-quarter revenue of approximately $928 million, up 17.6% year over year and above the $905.4 million consensus estimate. Subscription revenue rose 16% to $766.8 million. Veeva Announces Fiscal 2027 Second Quarter Results
• Positive Sentiment: Adjusted earnings reached $2.35 per share, exceeding the $2.22 consensus estimate and increasing from $1.99 a year earlier. The earnings and revenue beats were approximately 5.9% and 2.6%, respectively. Veeva Systems Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management issued above-consensus fiscal 2027 guidance, including revenue of about $3.7 billion versus a $3.6 billion estimate and EPS of $9.21 versus an $8.58 estimate. Third-quarter revenue guidance of $932 million-$935 million and EPS guidance of $2.33-$2.34 also topped analyst forecasts.
• Positive Sentiment: Biogen and Regeneron each committed to adopting Veeva Vault CRM globally. The wins reinforce Veeva’s competitive position in life-sciences customer relationship management and may support future subscription growth. Veeva Vault CRM Selected by Regeneron Veeva Vault CRM Selected by Biogen
• Neutral Sentiment: Piper Sandler initiated coverage, while Needham reaffirmed its Buy rating. These actions add analyst visibility but provide limited new information without detailed price targets or estimates.
• Neutral Sentiment: Despite the improving outlook, Veeva trades at a relatively elevated valuation, with a reported price-to-earnings ratio above 43. Future gains may therefore depend on continued execution and strong growth.

About Veeva Systems

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.